Sugammadex more rapidly and reliably reverses rocuronium-induced neuromuscular block compared with neostigmine, but it is not known if subsequent patient outcomes, including nausea, vomiting and other aspects of recovery are modified. In this study, we compared the recovery characteristics of sugammadex and neostigmine/glycopyrrolate following reversal of neuromuscular block. This was a single-centre, randomised, blinded, parallel-group clinical trial in women undergoing elective day-surgical laparoscopic gynaecological surgery, with a standardised general anaesthesia regimen that included rocuronium. Neuromuscular block was reversed with either sugammadex 2 mg.kg À1 or neostigmine 40 lg.kg À1 and glycopyrrolate 400 lg. The primary outcome was the incidence of nausea and vomiting during the first six postoperative hours. Secondary outcomes included other measures of postoperative recovery such as patient symptoms and recovery scores. Three-hundred and four women were analysed by intention-to-treat (sugammadex n = 151, neostigmine n = 153), which included four major protocol violations. There was no significant difference between sugammadex and neostigmine groups in the incidence of early nausea and vomiting (49.0% vs. 51.0%, respectively; OR 0.92, 95%CI 0.59-1.45; p = 0.731). Double vision (11.5% vs. 20.0%; p = 0.044) and dry mouth (71.6% vs. 85.5%; p = 0.003) were less common after sugammadex. Sedation scores at 2 h were also lower after sugammadex (median ( 
Introduction
Sugammadex (Bridion â , Schering-Plough Pty Ltd, MSD Australia) is more effective than neostigmine for the rapid and reliable reversal of neuromuscular block induced by rocuronium or vecuronium [1] . The potential time savings associated with this drug suggest that it could be cost effective [2] . However, other anticipated benefits such as a lower risk of major respiratory complications, or faster and better recovery with respect to patient-centred outcomes, have not been established [1] [2] [3] . Systematic and narrative reviews published in 2015 noted that randomised controlled trials were required to support or reject the hypothesis that patients experience better postoperative outcomes after sugammadex reversal [1, 3] . Postoperative nausea and vomiting (PONV) is common, and doses of neostigmine greater than 2.5 mg have been associated with an increased risk of PONV [4] . However, evidence-based analysis has found insufficient evidence that neostigmine confers a higher risk [5, 6] . Recommendations to minimise the dosage of neostigmine have been withdrawn from consensus guidelines for the management of PONV [7] .
There is clinical equipoise as to whether PONV is less frequent after reversal of neuromuscular block with sugammadex when compared with neostigmine. A meta-analysis of 17 randomised trials involving 1553 patients reported that the relative risk of nausea after sugammadex was 0.94 (95%CI 0.79-1.13), and of vomiting 0.87 (95%CI 0.67-1.17 [1] . Since this systematic review, several small studies have suggested that PONV may be transiently reduced in the first hour or so after reversal with sugammadex, although not subsequently [8] [9] [10] [11] . This positive finding is consistent with previous data [12, 13] but the quality of evidence is low, because all studies have been either retrospective cohort studies or small clinical trials with poor bias control such as inadequate blinding or power, or only positive findings for a secondary outcome.
There are minimal data about other patient symptoms and satisfaction during recovery from neuromuscular block after sugammadex. A small study using an uncontrolled convenience sample [9] assessed some recovery characteristics and found sugammadex to be superior to neostigmine.
The primary aim of this clinical trial was to compare the incidence of PONV associated with sugammadex and neostigmine/glycopyrrolate reversal of rocuronium-induced neuromuscular block during laparoscopic gynaecological surgery. Secondary outcomes assessed severity of PONV and functional aspects of patient recovery, including symptoms, readiness to discharge and quality of recovery on the first postoperative day. Our hypothesis was that sugammadex would be associated with a lower incidence of early PONV and improved overall patient recovery compared with neostigmine/glycopyrrolate.
Methods
This randomised, blinded, parallel-group, active control, single-centre clinical trial received institutional ethical approval from the Women and Newborn Health Service Ethics Committee of King Edward Memorial Hospital in Perth, Western Australia. The study was conducted between September 2011 and November 2016. All participants gave written informed consent.
We recruited patients at pre-admission clinics or the pre-operative day-surgical ward. Inclusion criteria were: ASA physical status 1-3; age 18-70 years; and scheduled day-surgical laparoscopic gynaecological procedure < 1 h under general anaesthesia, with neuromuscular block from rocuronium. Exclusion criteria were: need to avoid intravenous (i.v.) induction or neuromuscular block; nausea or vomiting within 48 h before surgery; pregnancy; contraindication to any study drug or scheduled anaesthetic drug; likelihood of extensive surgical procedures; and a major peri-operative change to the surgical plan or to the patient's daysurgical status.
A randomisation sequence for two groups in a 1:1 ratio was produced in blocks of four using a computer-generated random number sequence. After patient screening and randomisation, group allocation occurred immediately before anaesthesia using sealed, number-coded envelopes. The study drug was prepared by the attending anaesthetist (who had no further study involvement) using a 5-ml syringe, normal saline and the study drug dose based on actual body weight. Patients, postoperative recovery and ward staff, research nurse data collectors and the statistician were all blinded to group allocation.
General anaesthesia was standardised. Induction was with i.v. fentanyl 1-1.5 lg.kg À1 and propofol 1.5-2.5 mg.kg
À1
. Anaesthesia was maintained using sevoflurane, oxygen and air, aiming for an inspired oxygen concentration of 50% unless a higher concentration was needed because of the clinical condition of the patient. Intravenous rocuronium 0.6-0.8 mg.kg Baseline data were collected, including patient baseline characteristics, a pre-operative quality of recovery (QoR18) score [14] , a modified nine-item opioid-related Symptom Distress Scale (SDS) 0-36 score [15] and an Apfel PONV 0-4 risk score [16] . In the recovery room, PONV was assessed by observation of the number of episodes of vomiting or retching and 0-10 verbal numerical rating scores. Symptoms relevant to recovery of neuromuscular function were determined using direct observation and questioning, for example, the ability to swallow or the presence of 'double vision'. Pain was assessed using 0-10 verbal numerical rating scores, and time to readiness for discharge from the recovery room (based on departmental criteria) was documented. Postoperative nausea and vomiting was re-assessed at 2, 6 and 24 h postoperatively.
At 24 h, persistent symptoms were assessed by telephone interview. Postoperative nausea and vomiting was quantified using the 'clinically significant PONV score' [17] , the SDS and the need for anti-emetic drug treatment [15] . The quality of recovery score was reassessed, and patients asked to rate the normality of their bowel activity and their satisfaction with their overall recovery using a scale of excellent, good, fair or poor.
The primary outcome was the cumulative incidence of PONV in the first six postoperative hours. Based on data from our department after this type of surgery using single-drug PONV prophylaxis and reversal of neuromuscular block with neostigmine, we estimated that 60% of the patients would experience PONV during this period. An a priori calculation found that a total sample size of 360 (n = 180 per group) was required to demonstrate a 25% difference in incidence of PONV, based on power = 80% and a = 0.05.
Univariate comparisons of continuous data were made using the Mann-Whitney test, and the Chisquare or Fisher exact test was used for categorical comparisons. Postoperative time to anti-emetic medication and the duration of hospital stay were analysed using Kaplan-Meier survival curves and the log rank test. Values of p < 0.05 were considered statistically significant. Statistical analysis was performed using SPSS (version 20.0, IBM SPSS, Armonk, NY, IBM Corp).
Results
The trial was terminated early because we were unable to recruit sufficient numbers of participants. In total, 390 women were recruited, but 83 did not enter the study due to a late change in surgical plan, deferral of surgery or a surgical decision to organise in-patient admission. Three-hundred and seven patients were randomly allocated, but three had no data collected, leaving 304 for analysis (sugammadex n = 151, neostigmine n = 153, Fig. 1 ). At most, 11 (7.3%) and 14 (9.2%) women, in the sugammadex and neostigmine groups, respectively, were lost to follow-up at the 6-and 24-h time-points. Women lost to follow-up were similar to those analysed with respect to most baseline characteristics, but those lost to follow-up in the sugammadex group had a lower Apfel risk score than those in the neostigmine group.
There were 21 protocol violations (sugammadex n = 8, neostigmine n = 13), including four major violations when sugammadex was given to women allocated to receive neostigmine. Two of these patients received an unblinded 'rescue' dose of sugammadex after inadequate reversal, and two were given the incorrect study drug. All were analysed by intentionto-treat. The other 17 violations related to deviations from the standardised anaesthetic or postoperative analgesic regimen, including reversal before objective evidence of two twitches on a train-of-four stimulus (Fig. 1) .
Baseline characteristics of the groups (including the Apfel risk score for PONV) were similar (Table 1) . Intra-operative data showed no significant differences between groups (Table 1) .
The primary outcome measure (cumulative incidence of PONV from waking until 6 h after surgery) did not significantly differ between groups (49.0% vs. 51.0% in the sugammadex and neostigmine groups, respectively, OR 1.08, 95%CI 0.69-1.70, p = 0.73, Table 2 ).
Secondary assessment of PONV is detailed in Tables 2 and 3 . The incidence of nausea, nausea severity score, number of episodes of vomiting and the PONV intensity score were not significantly different between groups. The sugammadex group had a higher incidence of vomiting at the 24-h assessment (25.7% vs. 15.0%, p = 0.025). The timing of and treatment with anti-emetics (65% vs. 74%, sugammadex and neostigmine groups, respectively) did not significantly differ between groups (p = 0.087). Patient symptom distress and quality of recovery also did not significantly differ between groups (Table 3) .
Patients given sugammadex were less likely to have double vision (p = 0.044) and dry mouth (p = 0.003) after waking up in the recovery room, and dry mouth remained less common at 2 and 6 h postoperatively ( Table 2) .
Sedation scores at 2 h were lower in the sugammadex group compared with the neostigmine group (p = 0.021, Table 2 ).
Discussion
In this trial, sugammadex reversal of rocuroniuminduced non-depolarising neuromuscular block did not reduce the incidence or severity of nausea and vomiting after gynaecological laparoscopic surgery when compared with neostigmine reversal.
These findings are in contrast with those of several previous studies. Lee et al. in a large retrospective study (with propensity score matching to improve comparability) found lower frequency and severity of PONV after sugammadex reversal compared with pyridostigmine/glycopyrrolate reversal [10] . In a randomised double-blind trial of patients having extremity surgery without PONV prophylaxis by Koyuncu et al. [8] , PONV scores were lower on arrival in the recovery room following sugammadex, but the incidence of PONV in the first 24 h was high and did not differ significantly between sugammadex and neostigmine. Yagan et al. conducted a randomised trial in a mixed surgical population, and found that those patients receiving sugammadex had a lower incidence of PONV in the first postoperative hour (but not across 24 h), and required less treatment on the first postoperative day. Their patient groups were not matched for PONV risk (which may have confounded the results) and the dose of neostigmine used was larger than in our study [11] . Geldner et al. reported no significant difference in PONV, but acknowledged that their randomised controlled trial was underpowered to evaluate this outcome [18] .
Sugammadex n = 153
Intention-to-treat analysis n = 304 Sugammadex n = 2 no data collected Neostigmine n = 1 no data collected Cholinesterase inhibitors such as neostigmine act on cholinergic receptors in the brain emetic centre and gastro-intestinal tract, increasing oesophageal pressure, bowel secretions and motility. Theoretically, this could increase the incidence of postoperative nausea and vomiting, but it is now believed that this effect is not clinically significant following reversal of non-depolarising neuromuscular block [5] [6] [7] . Our findings support this conclusion.
There may be other patient-focussed benefits associated with sugammadex reversal of neuromuscular blockade when compared with anticholinesterase drugs such as neostigmine. It had been speculated that sugammadex, because it more reliably and completely reverses neuromuscular block [1, 19] , may also reduce postoperative respiratory complications in some patient populations. However, in a large, randomised clinical trial [3] this theoretical effect was not confirmed. It is also plausible that patients might feel better after sugammadex reversal due to the functional benefits of earlier complete return of muscle power and avoidance of cholinergic side-effects from neostigmine, or anticholinergic side-effects from glycopyrrolate or atropine. This has received little attention, although a pilot observational cohort study reported similar overall recovery, but better outcomes after sugammadex reversal in the nociceptive and physiological domains of the postoperative quality recovery scale, and more alert patients 40 min after surgery [9] . In that pilot study, patients were not randomly allocated to an intervention, were not treatment-blinded and the groups were not comparable with respect to several possible confounding variables. In another small trial investigating postoperative pain in the recovery room [13] , Castro et al. suggested that earlier discharge of patients who had received sugammadex might be appropriate, but that study was underpowered.
In our study, as was also observed by Amorin et al. [9] , patient sedation 2 h after surgery was less after sugammadex. Rapid immediate arousal and electroencephalographic changes have been described previously and attributed to the activation of muscle spindles, as muscle activity results in afferent input to brain arousal centres [20] . Although duration of stay in the recovery room did not differ between groups, this is influenced by multiple factors, only one of which is the level of arousal. Nevertheless, the secondary outcome finding of less early sedation after sugammadex is interesting and warrants further investigation.
We found that some symptoms were associated with neostigmine/glycopyrrolate reversal. Dry mouth may have been a side-effect of the anticholinergic drug, and blurred vision either a pharmacological effect of neostigmine or due to residual neuromuscular block. The latter is known to be very common in the recovery room after neostigmine reversal of rocuronium-induced neuromuscular block [21, 22] , and the incidence of diplopia of 20% in this study is consistent with what has been described in other studies. Although the implications of residual neuromuscular block in the recovery phase may be important from the patient experience perspective, the clinical relevance of dry mouth and temporary visual disturbance appears to be relatively minor, because patients receiving neostigmine did not have delayed discharge from the recovery room and did not report poorer functional recovery or lower satisfaction scores. There was also no apparent effect on bowel function, which is consistent with a randomised trial that reported no significant difference in the return of bowel activity when sugammadex and neostigmine were compared [23] .
The main strength of this study is that it is the largest randomised, blinded trial to specifically address a number of patient-focused, postoperative recovery outcomes after reversal of neuromuscular block with either sugammadex or neostigmine. The patient groups were homogeneous and well-matched for risk of PONV. A number of recovery variables were evaluated using validated assessment tools. The study terminated after the recruitment of approximately 150 out of 180 women in each group, mainly due to recruitment problems following changes in clinical practice over a period of years, especially greater use of multi-drug anti-emetic prophylaxis and total intravenous anaesthesia. Early study termination would usually be considered a limitation, but in this case it may not be important, given that approximately 83% of women in each treatment arm were recruited and the incidence of PONV in the groups was very similar (49% vs. 51%). This suggests it is very unlikely that a different conclusion would have been reached has we recruited an additional 30 women per group.
In conclusion, our findings did not provide evidence that reversal of neuromuscular block with sugammadex results in less early postoperative nausea and vomiting when compared with neostigmine/glycopyrrolate. Symptoms such as dry mouth and diplopia were less common and patients were less sedated, but there was no difference in other secondary outcome measures of patient recovery. 
